Experimental drug for advanced bone or soft tissue sarcoma
Part of Cancer clinical trials.
This trial tests an experimental drug, SOT106, that targets a specific marker on sarcoma cells. It aims to see if the drug is safe and effective in treating advanced osteosarcoma or soft tissue sarcoma when other treatments have not helped.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older (most participants are adults; teens may join in later parts of the study).
- You must have osteosarcoma or soft tissue sarcoma that has spread or cannot be removed by surgery, and standard treatments have not worked or caused too many side effects.
- You must have a tumor sample showing a specific marker (LRRC15) — this is checked with a lab test, either from a stored sample or a new biopsy.
- You must be in fairly good general health (able to care for yourself, with a life expectancy of at least 3 months).
- You must have adequate blood counts, kidney, liver, and heart function (tests will confirm this).
- You must agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HS-20093, combined with other treatments for people with advanced bone or soft tissue sarcoma. The goal is to see if these combinations can shrink tumors or slow their growth.
This trial tests a new combination therapy: an injected virus (OVV-01) alongside an immunotherapy drug (AK112) for people with advanced soft tissue sarcoma that hasn't responded to usual treatments. The aim is to see if this approach can help shrink tumors or slow their growth.
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
This study tests a personalized vaccine made from your tumor's unique mutations, combined with special immune cells grown from your blood, to treat advanced sarcoma (bone or soft tissue cancer) that did not respond to initial treatment. The goal is to help your immune system recognize and attack cancer cells.
This trial tests a new way of giving radiation therapy (called spatially fractionated radiotherapy) combined with a treatment strategy called PraG (pembrolizumab and granulocyte-macrophage colony-stimulating factor) for people with soft tissue sarcoma that cannot be removed or has spread. The goal is to see if the combination can help shrink or control the cancer.
This trial is testing a new combination of four treatments (an experimental drug, two chemo-like drugs, and radiation) for advanced soft tissue sarcoma that hasn't responded to earlier treatments. The goal is to see if this combination can help shrink or slow the cancer.
Hear when a new Osteosarcoma Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.